All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer

被引：0
|
作者：
Hesham Tawfik
Yousri Rostom
Hesham Elghazaly
机构：
[1] Tanta University,Clinical Oncology Department
[2] Alexandria University,Clinical Oncology Department
[3] Ain Shams University,Clinical Oncology Department
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 71卷
关键词：
Oral therapy; First-line chemotherapy; Metastatic breast cancer; HER2/Neu-negative;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：913 / 919
页数：6
相关论文
共 50 条
  • [21] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    Altundag, Kadri
    TUMORI JOURNAL, 2015, 101 (04): : 418 - 423
  • [22] Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
    Valerio, Maria Rosaria
    Spadaro, Pietro
    Arcana, Concetta
    Borsellino, Nicolo
    Cipolla, Calogero
    Vigneri, Paolo
    Piazza, Dario
    Gebbia, Vittorio
    FUTURE SCIENCE OA, 2021, 7 (10):
  • [23] A phase II trial of split, low-dose docetaxel and low-dose capecitabine:: A tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer
    Silva, Orlando
    Lopes, Gilberto
    Morgenzstern, Daniel
    Lobo, Christopher
    Doliny, Philomena
    Santos, Edgardo
    Abdullah, Sakher
    Gautam, Umang
    Reis, Isildinha
    Welsh, Catherine
    Slingerland, Joyce
    Hurley, Judith
    Gluck, Stefan
    CLINICAL BREAST CANCER, 2008, 8 (02) : 162 - 167
  • [24] Preliminary results of a phase II study of lipoplatin (liposomal cisplatin)-vinorelbine combination as first line treatment in HER2/neu negative metastatic breast cancer (MBC)
    Farhat, F.
    Kattan, J.
    Ibrahim, K.
    Bitar, N.
    Haddad, N.
    Tamraz, S.
    Hatoum, H.
    Shamseddine, A.
    EJC SUPPLEMENTS, 2010, 8 (03): : 192 - 192
  • [25] Epirubicin-vinorelbine intravenous combination followed by oral vinorelbine as first-line treatment in metastatic breast cancer
    Ardizzoia, Antonio
    Colombo, Ilaria
    Giordano, Monica
    Aglione, Stefania
    Isa, Luciano
    Scanni, Alberto
    Scognamiglio, Giovanni
    Bertolini, Alessandro
    Villa, Federica
    Gardani, Gianstefano
    TUMORI JOURNAL, 2007, 93 (06): : 544 - 549
  • [26] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.
    Altundag, Kadri
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan Saim
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): First results of an international phase II trial.
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Majois, F.
    Espie, M.
    Aubert, D.
    Bourlard, T.
    Villanova, G.
    Conte, P-F
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S280 - S280
  • [28] Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer
    Nolè, F
    Catania, C
    Sanna, G
    Imadalou, K
    Munzone, E
    Adamoli, L
    Longerey, B
    Blanchot, G
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 2006, 17 (02) : 322 - 329
  • [29] ACTIVITY AND SAFETY OF THREE-WEEKLY TRASTUZUMAB (T) PLUS AN ALL-ORAL COMBINATION OF VINORELBINE (VNR) AND CAPECITABINE (CAP) AS FIRST-LINE TREATMENT IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): A PROSPECTIVE PHASE II STUDY
    Palumbo, Raffaella
    Bernardo, Antonio
    Strada, Maria Rosa
    Poggi, Guido
    Teragni, Cristina
    Amatu, Alessio
    Montagna, Benedetta
    Tagliaferri, Barbara
    Sottotetti, Federico
    Frascaroli, Mara
    Bernardo, Giovanni
    ANNALS OF ONCOLOGY, 2009, 20
  • [30] Her2/neu Overexpressing Breast Cancer Patients Retain an Immunological Proficiency Compromised in Her2/neu-Negative Cases
    Simona, S. S. S.
    Muraro, E. M. E.
    Miolo, G. G. M.
    Martorelli, D. M. D.
    Turchet, E. T. E.
    Comaro, E. C. E.
    Talamini, R. T. R.
    Veronesi, A. V. A.
    Crivellari, D. C. D.
    Dolcetti, R. D. R.
    CANCER RESEARCH, 2010, 70
12345